University of Oxford, John Radcliffe Hospital, Nuffield Department of Surgery, Headley Way, Oxford, OX3 9DU, UK.
Expert Opin Ther Targets. 2010 Aug;14(8):797-824. doi: 10.1517/14728222.2010.499360.
Dendritic cells (DCs) have an important role, both direct and indirect, in controlling the expansion and function of T cells. Of the different subsets of T cells, cytotoxic T lymphocytes (CTLs/CD8(+) T cells) have been implicated in the pathogenesis and development of many diseases, including various forms of autoimmunity and transplant rejection. It may therefore be of therapeutic benefit to control the function of CTL in order to modulate disease processes and to ameliorate disease symptoms. Currently, pharmacological approaches have been employed to either directly or indirectly modulate the function of T cells. However, these treatment strategies have many limitations. Many experimental data have suggested that it is possible to alter CTL activity through manipulation of DC.
Novel strategies that condition DCs to influence disease outcome through manipulation of CTL activity, both directly and indirectly. This includes the modulation of co-stimulation, negative co-stimulation, as well as manipulation of the cytokine milieu during CTL generation. Furthermore, DCs may also impact CTL activity through effects on effector and regulatory cells, along with manipulation of bioenergetic regulation, apoptotic-cell mediated tolerance and through the generation of exosomes. The implications of related interventions in the clinical arena are in turn considered.
Insight into such indirect methods of controlling CTL activity allows for an understanding of how disease-specific T cells may be regulated, while also sparing other aspects of adaptive immunity for normal physiological function. Such an approach towards the treatment of disease represents an innovative therapeutic target in the clinical arena.
There are numerous innovative methods for using DCs to control CTL responses. Manipulation of this interaction is thus an attractive avenue for the treatment of disease, particularly those of immune dysregulation, such as seen in autoimmunity and transplantation. With the number of studies moving into clinical stages constantly increasing, further advances and successes in this area are inevitable.
树突状细胞 (DC) 在控制 T 细胞的扩增和功能方面具有直接和间接的重要作用。在不同的 T 细胞亚群中,细胞毒性 T 淋巴细胞 (CTL/CD8(+) T 细胞) 已被牵连到许多疾病的发病机制和发展中,包括各种形式的自身免疫和移植排斥。因此,控制 CTL 的功能可能具有治疗益处,以调节疾病过程并改善疾病症状。目前,已经采用了药理学方法来直接或间接地调节 T 细胞的功能。然而,这些治疗策略有许多局限性。许多实验数据表明,通过操纵 DC 有可能改变 CTL 的活性。
通过操纵 DC 直接和间接影响 CTL 活性从而影响疾病结果的新型策略。这包括调节共刺激、负共刺激以及在 CTL 生成过程中操纵细胞因子微环境。此外,DC 还可以通过对效应和调节细胞的影响以及对生物能量调节、凋亡细胞介导的耐受和外泌体的产生的操纵来影响 CTL 活性。反过来,还考虑了相关干预措施在临床领域的意义。
深入了解控制 CTL 活性的间接方法可以帮助理解如何调节疾病特异性 T 细胞,同时为正常生理功能保留适应性免疫的其他方面。这种针对疾病的治疗方法代表了临床领域的一个创新治疗靶点。
有许多使用 DC 控制 CTL 反应的创新方法。因此,操纵这种相互作用是治疗疾病的一个有吸引力的途径,特别是那些免疫失调的疾病,如自身免疫和移植中所见的疾病。随着越来越多的研究进入临床阶段,该领域的进一步进展和成功是不可避免的。